Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alkermes plc (NASDAQ:ALKS – Free Report) – Analysts at Zacks Research lifted their Q3 2025 earnings per share estimates for Alkermes in a report released on Wednesday, April 10th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.52 for the quarter, up from their prior estimate of […]
Alkermes plc (NASDAQ:ALKS – Free Report) – Equities researchers at Leerink Partnrs reduced their FY2027 earnings estimates for Alkermes in a research report issued on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $1.35 for the year, down from their prior estimate of $1.45. […]
A closer look at one of the leaders in the global bipolar disorder treatment market
Alkermes plc (NASDAQ:ALKS – Free Report) – Research analysts at Leerink Partnrs dropped their FY2027 earnings per share (EPS) estimates for shares of Alkermes in a research note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $1.35 for the year, […]
Alkermes plc announced positive results from a phase 1b study evaluating ALKS 2680 for treating narcolepsy type 2 and idiopathic hypersomnia.